Skip to content

Elucidation of the effect of Lacticaseibacillus paracasei Shirota strain (LcS) in human intestine

Elucidation of the effect of Lacticaseibacillus paracasei Shirota strain (LcS) in human intestine

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs021220028
Enrollment
10
Registered
2022-11-17
Start date
2022-11-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A N/A

Interventions

Oral Yakult 1000 given on daily for 30 days from 44 to 71 days after the start of the test.

Sponsors

Chinda Daisuke
Lead Sponsor
Fukuda Shinsaku
Collaborator

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Healthy men over 20 years old

Exclusion criteria

Exclusion criteria: Subjects with milk and / or soy allergies. Subjects who refused to participate. Subjects with a history of gastrointestinal surgery Subjects with oral medication due to a previous ill ness who refused to participate.

Design outcomes

Primary

MeasureTime frame
Gene expression in host cells of the intestinal mucosa

Secondary

MeasureTime frame
1)LcS gene expression in intestinal contents 2)Microspatial analysis of LcS in feces, intestinal contents, and mucosal scraped samples 3)Bacterial flora composition in feces, intestinal contents, and mucosal scraped samples 4)Organic acid concentration in feces and intestinal contents

Contacts

Public ContactDaisuke Chinda

Hirosaki University Hospital

chinda@hirosaki-u.ac.jp+81-172-33-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026